X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (4380) 4380
Publication (3) 3
Book Chapter (2) 2
Magazine Article (2) 2
Book / eBook (1) 1
Dissertation (1) 1
Web Resource (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
pyridones - pharmacology (2867) 2867
humans (2430) 2430
animals (1968) 1968
male (1302) 1302
pharmacology & pharmacy (1100) 1100
female (925) 925
pyridones - therapeutic use (921) 921
pyridones - chemistry (726) 726
rats (721) 721
mice (656) 656
pyridones - administration & dosage (567) 567
chemistry, medicinal (560) 560
milrinone (474) 474
pyridones - chemical synthesis (473) 473
structure-activity relationship (450) 450
dose-response relationship, drug (438) 438
biochemistry & molecular biology (401) 401
middle aged (392) 392
cell line, tumor (380) 380
administration, oral (374) 374
pyridones - pharmacokinetics (365) 365
adult (364) 364
pyridones - adverse effects (344) 344
aged (329) 329
oncology (303) 303
molecular structure (301) 301
analysis (278) 278
rivaroxaban (274) 274
antineoplastic agents - pharmacology (271) 271
in vitro techniques (265) 265
pyrazoles - therapeutic use (264) 264
cardiotonic agents - pharmacology (242) 242
anticoagulants (239) 239
cancer (232) 232
phosphodiesterase inhibitors - pharmacology (231) 231
apixaban (228) 228
dabigatran (228) 228
cell proliferation - drug effects (226) 226
expression (220) 220
treatment outcome (220) 220
chemistry, organic (216) 216
iron chelating agents - pharmacology (216) 216
protein kinase inhibitors - pharmacology (213) 213
pharmacokinetics (212) 212
imidazoles - pharmacology (211) 211
models, molecular (210) 210
pyrazoles - pharmacology (209) 209
rats, sprague-dawley (208) 208
anticoagulants - therapeutic use (205) 205
pirfenidone (205) 205
deferiprone (201) 201
research (199) 199
mutation (197) 197
pyrimidinones - pharmacology (196) 196
dogs (195) 195
cells, cultured (192) 192
disease models, animal (191) 191
pyridones - metabolism (191) 191
activation (190) 190
myocardial contraction - drug effects (190) 190
time factors (186) 186
cardiac & cardiovascular systems (183) 183
hematology (183) 183
warfarin (183) 183
cell biology (180) 180
kinetics (180) 180
inhibition (171) 171
anti-bacterial agents - pharmacology (168) 168
microbial sensitivity tests (165) 165
pyrazoles - administration & dosage (163) 163
therapy (163) 163
pharmacology (159) 159
enzyme inhibitors - pharmacology (154) 154
cell line (152) 152
drug therapy (152) 152
hemodynamics - drug effects (152) 152
prevention (152) 152
pyridones (152) 152
apoptosis (151) 151
drug design (151) 151
pyrazoles - adverse effects (150) 150
safety (144) 144
apoptosis - drug effects (143) 143
atrial fibrillation - drug therapy (143) 143
care and treatment (143) 143
in-vitro (143) 143
inhibitors (142) 142
antifungal agents - pharmacology (140) 140
medicine & public health (139) 139
rats, wistar (139) 139
efficacy (138) 138
pyrimidines - pharmacology (137) 137
toxicology (136) 136
pyridines - pharmacology (134) 134
chemistry, multidisciplinary (132) 132
guinea pigs (132) 132
anticoagulants - administration & dosage (131) 131
atrial fibrillation (131) 131
iron - metabolism (131) 131
phosphorylation (131) 131
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (4194) 4194
Japanese (119) 119
German (100) 100
Chinese (23) 23
French (22) 22
Polish (15) 15
Spanish (11) 11
Russian (9) 9
Italian (7) 7
Dutch (4) 4
Czech (3) 3
Hungarian (2) 2
Danish (1) 1
Hebrew (1) 1
Korean (1) 1
Norwegian (1) 1
Portuguese (1) 1
Romanian (1) 1
Swedish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal of the American College of Cardiology, ISSN 0735-1097, 2014, Volume 64, Issue 11, pp. 1128 - 1139
Abstract Background Non–vitamin K oral anticoagulants (NOACs) do not require routine laboratory monitoring. However, laboratory measurement may be desirable in... 
Cardiovascular | Internal Medicine | dabigatran | rivaroxaban | monitoring | laboratory | apixaban | MEASURING RIVAROXABAN | CARDIAC & CARDIOVASCULAR SYSTEMS | DIRECT THROMBIN INHIBITOR | DABIGATRAN CONCENTRATIONS | PROTHROMBIN TIME | PARTIAL THROMBOPLASTIN TIME | COAGULATION ASSAYS | IN-VITRO | FACTOR-XA INHIBITOR | PLASMA-CONCENTRATIONS | INTERNATIONAL NORMALIZED RATIO | Anticoagulants - administration & dosage | Humans | Antithrombins - administration & dosage | Thiophenes - administration & dosage | Dabigatran | Factor Xa Inhibitors - administration & dosage | Antithrombins - pharmacology | Pyridones - administration & dosage | Rivaroxaban | Benzimidazoles - administration & dosage | beta-Alanine - pharmacology | Factor Xa Inhibitors - pharmacology | beta-Alanine - analogs & derivatives | Pyrazoles - pharmacology | Administration, Oral | Morpholines - administration & dosage | beta-Alanine - administration & dosage | Morpholines - pharmacology | Thiophenes - pharmacology | Pyrazoles - administration & dosage | Partial Thromboplastin Time | Anticoagulants - pharmacology | Benzimidazoles - pharmacology | Drug Monitoring | Pyridones - pharmacology | Measurement | Anticoagulants (Medicine) | Vitamins | Studies | Anticoagulants | Plasma | Bibliographic literature | Laboratories | Drug therapy | Drug dosages | Bone surgery
Journal Article
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, ISSN 1555-9041, 02/2019, Volume 14, Issue 2, pp. 278 - 287
Journal Article
Toxicology and applied pharmacology, ISSN 0041-008X, 01/2014, Volume 274, Issue 2, pp. 328 - 338
Induction of fibrosis during prolonged culture of precision-cut liver slices (PCLS) was reported. In this study, the use of rat PCLS was investigated to... 
Early onset of fibrosis | Precision-cut liver slices | Antifibrotic drugs | Liver fibrosis | Ex vivo model | ROSMARINIC ACID | ANGIOTENSIN-II | ANTI-FIBROTIC DRUGS | IN-VITRO | INHIBITS ACTIVATION | HEPATIC STELLATE CELLS | ENDOPLASMIC-RETICULUM | DERMAL FIBROBLASTS | GROWTH-FACTOR | IMATINIB MESYLATE | PHARMACOLOGY & PHARMACY | TOXICOLOGY | Niacinamide - analogs & derivatives | Rats, Wistar | Transforming Growth Factor beta1 - antagonists & inhibitors | Transforming Growth Factor beta1 - metabolism | Male | Valproic Acid - pharmacology | Depsides - pharmacology | Perindopril - pharmacology | Collagen Type I - genetics | Liver - drug effects | Benzamides - pharmacology | Benzylisoquinolines - pharmacology | Organ Culture Techniques | Liver Cirrhosis - drug therapy | Gene Expression | Collagen Type I - metabolism | Proto-Oncogene Proteins c-sis - genetics | Proto-Oncogene Proteins c-sis - metabolism | Down-Regulation | Liver - metabolism | Rats | Becaplermin | Transforming Growth Factor beta1 - genetics | Pyrimidines - pharmacology | Cinnamates - pharmacology | HSP47 Heat-Shock Proteins - genetics | Imatinib Mesylate | Piperazines - pharmacology | Animals | Models, Biological | Sorafenib | HSP47 Heat-Shock Proteins - metabolism | Connective Tissue Growth Factor - genetics | Phenylurea Compounds - pharmacology | Niacinamide - pharmacology | Connective Tissue Growth Factor - metabolism | Pyridones - pharmacology | Proto-Oncogene Proteins c-sis - antagonists & inhibitors | Drugs | Liver diseases | Analysis | Liver | Fibrosis | Gene expression | Growth factors | Index Medicus | FIBROSIS | DRUGS | GENES | LIVER | RATS | 60 APPLIED LIFE SCIENCES | ATP
Journal Article
PloS one, ISSN 1932-6203, 2014, Volume 9, Issue 12, p. e111840
... transduction and chromatin modification has been facilitated by interfacing the sciences of chemical biology and pharmacology [5], [6]. For example, the availability... 
PROTEIN METHYLTRANSFERASES | SELECTIVE-INHIBITION | MOLECULAR SUBTYPES | APOPTOSIS | B-CELL LYMPHOMA | MULTIDISCIPLINARY SCIENCES | DRUG DISCOVERY | RESISTANCE | MECHANISMS | CANCER | SOMATIC MUTATIONS | Enhancer of Zeste Homolog 2 Protein - antagonists & inhibitors | Neoplasm Transplantation | Vincristine - pharmacology | Humans | Receptors, Glucocorticoid - metabolism | Antineoplastic Combined Chemotherapy Protocols - pharmacology | Receptors, Glucocorticoid - agonists | Dexamethasone - pharmacology | Female | Antineoplastic Agents - pharmacology | Benzamides - pharmacology | Gene Expression Regulation, Neoplastic - drug effects | Drug Evaluation, Preclinical | Lymphoma, Non-Hodgkin - drug therapy | Enhancer of Zeste Homolog 2 Protein - metabolism | Random Allocation | Mice, SCID | Prednisolone - pharmacology | Animals | Cyclophosphamide - pharmacology | Lymphoma, Non-Hodgkin - metabolism | Cell Line, Tumor | Glucocorticoids - pharmacology | Prednisone - pharmacology | Doxorubicin - pharmacology | Pyridones - pharmacology | Care and treatment | Corticosteroids | Fluocinolone acetonide | Central nervous system depressants | Analysis | Histones | Models | Non-Hodgkin's lymphomas | Immunosuppressive agents | Steroids | Cancer | Enzymes | Dexamethasone | Glucocorticoids | Research & development--R&D | Gene expression | Lymphoma | Anticancer properties | Signal transduction | Cell growth | Inhibitors | Lymphomas | Mutation | Prednisolone | Apoptosis | Research & development | R&D
Journal Article
Nature communications, ISSN 2041-1723, 2014, Volume 5, Issue 1, p. 5712
Increased expression of the Microphthalmia-associated transcription factor (MITF) contributes to melanoma progression and resistance to BRAF pathway... 
BRAF INHIBITION | TYROSINE KINASE AXL | RAF INHIBITION | CELLS | BREAST-CANCER METASTASIS | MULTIDISCIPLINARY SCIENCES | ACQUIRED-RESISTANCE | IMPROVED SURVIVAL | MEK INHIBITORS | UP-REGULATION | CONFERS RESISTANCE | Prognosis | Skin Neoplasms - drug therapy | Humans | Gene Expression Regulation, Neoplastic | Extracellular Signal-Regulated MAP Kinases - metabolism | Extracellular Signal-Regulated MAP Kinases - genetics | Melanoma - genetics | Receptor Protein-Tyrosine Kinases - antagonists & inhibitors | Indoles - pharmacology | Pyrimidinones - pharmacology | Antineoplastic Agents - pharmacology | Benzamides - pharmacology | Proto-Oncogene Proteins B-raf - metabolism | Melanoma - metabolism | Proto-Oncogene Proteins - metabolism | Skin Neoplasms - pathology | Proto-Oncogene Proteins - antagonists & inhibitors | Microphthalmia-Associated Transcription Factor - metabolism | Signal Transduction | Proto-Oncogene Proteins - genetics | Imidazoles - pharmacology | Melanoma - pathology | Pyrimidines - pharmacology | Receptor Protein-Tyrosine Kinases - metabolism | Sulfonamides - pharmacology | Imatinib Mesylate | Piperazines - pharmacology | Skin Neoplasms - metabolism | Proto-Oncogene Proteins B-raf - antagonists & inhibitors | Xenograft Model Antitumor Assays | Drug Resistance, Neoplasm - genetics | Animals | Receptor Protein-Tyrosine Kinases - genetics | Proto-Oncogene Proteins B-raf - genetics | Aminopyridines - pharmacology | Melanoma - drug therapy | Skin Neoplasms - genetics | Cell Line, Tumor | Oximes - pharmacology | Mice | Protein Kinase Inhibitors - pharmacology | Microphthalmia-Associated Transcription Factor - genetics | Pyridones - pharmacology
Journal Article
Journal Article
Nature immunology, ISSN 1529-2916, 2014, Volume 15, Issue 8, pp. 717 - 726
Journal Article
Thrombosis and Haemostasis, ISSN 0340-6245, 08/2010, Volume 104, Issue 2, pp. 302 - 310
Journal Article